Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06966674

No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track

This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

No-reflow Cardiovascular Diseases Heart Diseases Infarction Intracoronary Ischemia Myocardial Infarction Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms ST Elevation Myocardial Infarction STEMI Tirofiban Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kafrelsheikh University

Kafr ash Shaykh, Kafrelsheikh, 33516, Egypt

Location status: Recruiting

Location contact

Mohamed K Salama, MD

PRINCIPAL_INVESTIGATOR

Mohammed A Hammad, MD

CONTACT

[email protected]

00201015928694

Wael A Hassib, MD

PRINCIPAL_INVESTIGATOR

About this study

ST-segment-elevation myocardial infarction (STEMI) is most commonly caused by rupture or erosion of an atherosclerotic plaque, resulting in acute occlusion of the coronary artery, and the preferred reperfusion strategy is primary percutaneous coronary intervention (PCI).

The no-reflow phenomenon is one of the most common causes of adverse cardiovascular events in patients STEMI.

In recent years, mechanical or pharmacological treatment strategies including adjunctive administration of glycoprotein IIb/IIIa inhibitors (GPI) have been proposed in patients with STEMI.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old.
  • Both sexes.
  • Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain >30 minutes with ST-segment elevation of >1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.

Exclusion criteria

  • Treatment with thrombolytic drugs in the previous 24 hours.
  • Known malignancy.
  • Thrombocytopenia.
  • End-stage liver disease.
  • Cardiogenic shock.
  • Renal failure with glomerular filtration<30 ml/min.
  • Contraindication for the use of tirofiban.

Treatment and study plan

Intracoronary tirofiban

Drug

Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg).

Other names: Aggrastat

saline 0.9%

Drug

Patients will receive intracoronary saline 0.9% solution as a control group.

Primary outcomes

  1. Blood stream

    Time frame: After treatment (Up to 15 minutes)

    Blood stream in coronary artery before and after treatment, including Thrombolysis in Myocardial Infarction (TIMI) flow grade in IRAs, coronary blood flow will be calculated with TIMI frame count method.

Secondary outcomes

  1. Incidence of major adverse cardiac events

    Time frame: After treatment (Up to 30 days)

    Incidence of major adverse cardiac events were recorded.

Study contacts

Contact information is provided by the study sponsor or research team.

Mohammed A Hammad, MD

CONTACT

[email protected]

00201015928694

Sponsors and collaborators

Lead sponsor

Kafrelsheikh University

Other

Registry information

Official study title

Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
May 13, 2025
Registry last updated
May 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.